Disease details

Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

5 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05359653 (ClinicalTrials.gov)	March 22, 2023	28/4/2022	Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy	A Randomized, Double-Blind, Delayed Treatment, Placebo-Controlled Trial to Assess the Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy	Multiple Sclerosis (MS);Multiple Sclerosis, Relapsing-Remitting;Multiple Sclerosis, Primary Progressive;Multiple Sclerosis, Chronic Progressive;Multiple Sclerosis Relapse;Multiple Sclerosis Brain Lesion;Multiple Sclerosis Benign	Drug: Clemastine Fumarate;Drug: Placebo	University of California, San Francisco	United States Department of Defense	Not yet recruiting	18 Years	55 Years	All	74	Phase 1/Phase 2	United States
2	NCT05338450 (ClinicalTrials.gov)	August 30, 2022	6/4/2022	Clemastine Fumarate as Remyelinating Treatment in Internuclear Ophthalmoparesis and Multiple Sclerosis	Clemastine Fumarate as Remyelinating Treatment in Internuclear Ophthalmoparesis and Multiple Sclerosis	Multiple Sclerosis;Internuclear Ophthalmoplegia	Drug: Clemastine Fumarate;Drug: Placebo	Amsterdam UMC, location VUmc	NULL	Recruiting	18 Years	70 Years	All	80	Phase 3	Netherlands
3	EUCTR2021-003677-66-NL (EUCTR)	14/02/2022	16/12/2021	Clemastine fumarate as a treament for eye movement disorders in patients with multiple sclerosis	Clemastine fumarate as remyelinating treatment in internuclear ophthalmoparesis and multiple sclerosis - RESTORE	Multiple sclerosis (MS)Internuclear ophthalmoparesis (INO) MedDRA version: 21.0;Level: LLT;Classification code 10080865;Term: Multiple sclerosis lesion;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Clemastine Milstein 1 mg, tabletten Product Name: Clemastine fumarate INN or Proposed INN: CLEMASTINE FUMARATE Trade Name: Fampyra 10 mg prolonged-release tablets Product Name: Fampridine INN or Proposed INN: Fampridine	Amsterdam University Medical Center	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	80	Phase 3	Netherlands
4	NCT03109288 (ClinicalTrials.gov)	August 11, 2017	11/4/2017	Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)	Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)	Multiple Sclerosis	Drug: Pioglitazone;Drug: clemastine fumarate;Drug: Dantrolene;Drug: Pirfenidone	National Institute of Allergy and Infectious Diseases (NIAID)	NULL	Recruiting	18 Years	N/A	All	250	Phase 1/Phase 2	United States
5	NCT02040298 (ClinicalTrials.gov)	January 2014	10/1/2014	Assessment of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis	A Phase II Randomized, Double-Blind, Parallel-Group, Placebo Controlled Crossover Trial to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis	Multiple Sclerosis, Relapsing-Remitting	Drug: Clemastine;Drug: Placebo	University of California, San Francisco	NULL	Completed	18 Years	60 Years	Both	50	Phase 2	United States